Work for Axovant Gene Therapies Ltd.?

Claim Your Profile

Axovant Gene Therapies Ltd. Logo Image

Axovant Gene Therapies Ltd.

Axovant Gene Therapies Ltd. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on

2020 Form 10K

Axovant Gene Therapies Ltd.

Axovant Gene Therapies Ltd. has reached its limit for free report views.

About Axovant Gene Therapies Ltd.

11-50 Employees
Based in New York City, New York

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Their current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol